Skip to content

Arvinas ARVN Free cash flow yield

Free cash flow yield at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-16.6%-0.6pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-3.6%-1.5pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-1.5%-12.2pp
Immunome logo
ImmunomeIMNM
-8.3%-3.4pp
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-24.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-13.4%-6.1pp

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's free cash flow yield?
Arvinas (ARVN) reported free cash flow yield of -37.9% in Q1 2026.
What is the long-term trend for Arvinas's free cash flow yield?
Over 4 years (2020 to 2025), Arvinas's free cash flow yield has grown at a 102.8% compound annual growth rate (CAGR), from -2.1% to -36.2%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.